These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26062848)

  • 61. Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling.
    Moharram SA; Chougule RA; Su X; Li T; Sun J; Zhao H; Rönnstrand L; Kazi JU
    Oncotarget; 2016 Sep; 7(36):57770-57782. PubMed ID: 27458164
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
    Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
    Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
    Agrawal S; Koschmieder S; Bäumer N; Reddy NG; Berdel WE; Müller-Tidow C; Serve H
    Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).
    Rosen DB; Minden MD; Kornblau SM; Cohen A; Gayko U; Putta S; Woronicz J; Evensen E; Fantl WJ; Cesano A
    PLoS One; 2010 Oct; 5(10):e13543. PubMed ID: 21048955
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
    Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
    Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
    [TBL] [Abstract][Full Text] [Related]  

  • 68. GATM-Mediated Creatine Biosynthesis Enables Maintenance of FLT3-ITD-Mutant Acute Myeloid Leukemia.
    Zhang Y; Newsom KJ; Zhang M; Kelley JS; Starostik P
    Mol Cancer Res; 2022 Feb; 20(2):293-304. PubMed ID: 34635505
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
    Zhang Y; Hsu CP; Lu JF; Kuchimanchi M; Sun YN; Ma J; Xu G; Zhang Y; Xu Y; Weidner M; Huard J; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):675-91. PubMed ID: 25326874
    [TBL] [Abstract][Full Text] [Related]  

  • 70. NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.
    Kowolik CM; Lin M; Xie J; Overman LE; Horne DA
    Oncotarget; 2016 Dec; 7(52):86186-86197. PubMed ID: 27863389
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression.
    Zhang D; Guo Y; Zhao Y; Yu L; Chang Z; Pei H; Huang J; Chen C; Xue H; Xu X; Pan Y; Li N; Zhu C; Zhao ZJ; Yu J; Chen Y
    Microb Cell Fact; 2021 Mar; 20(1):67. PubMed ID: 33691697
    [TBL] [Abstract][Full Text] [Related]  

  • 72. miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
    Wallace JA; Kagele DA; Eiring AM; Kim CN; Hu R; Runtsch MC; Alexander M; Huffaker TB; Lee SH; Patel AB; Mosbruger TL; Voth WP; Rao DS; Miles RR; Round JL; Deininger MW; O'Connell RM
    Blood; 2017 Jun; 129(23):3074-3086. PubMed ID: 28432220
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control.
    Reddy PN; Sargin B; Choudhary C; Stein S; Grez M; Müller-Tidow C; Berdel WE; Serve H; Brandts CH;
    Blood; 2012 Aug; 120(8):1691-702. PubMed ID: 22517899
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality.
    Schmidt-Arras D; Böhmer SA; Koch S; Müller JP; Blei L; Cornils H; Bauer R; Korasikha S; Thiede C; Böhmer FD
    Blood; 2009 Apr; 113(15):3568-76. PubMed ID: 19204327
    [TBL] [Abstract][Full Text] [Related]  

  • 75. STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia.
    Sueur G; Boutet A; Gotanègre M; Mansat-De Mas V; Besson A; Manenti S; Bertoli S
    Sci Rep; 2020 Feb; 10(1):1906. PubMed ID: 32024878
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.
    Liu S; Yin L; Stroopinsky D; Rajabi H; Puissant A; Stegmaier K; Avigan D; Kharbanda S; Kufe D; Stone R
    Blood; 2014 Jan; 123(5):734-42. PubMed ID: 24282218
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.
    Spohr C; Poggio T; Andrieux G; Schönberger K; Cabezas-Wallscheid N; Boerries M; Halbach S; Illert AL; Brummer T
    Leukemia; 2022 Apr; 36(4):970-982. PubMed ID: 34903841
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression of GADS enhances FLT3-induced mitogenic signaling.
    Chougule RA; Cordero E; Moharram SA; Pietras K; Rönnstrand L; Kazi JU
    Oncotarget; 2016 Mar; 7(12):14112-24. PubMed ID: 26895103
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling.
    Caldarelli A; Müller JP; Paskowski-Rogacz M; Herrmann K; Bauer R; Koch S; Heninger AK; Krastev D; Ding L; Kasper S; Fischer T; Brodhun M; Böhmer FD; Buchholz F
    Leukemia; 2013 Dec; 27(12):2301-10. PubMed ID: 23508117
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia.
    Bjelosevic S; Gruber E; Newbold A; Shembrey C; Devlin JR; Hogg SJ; Kats L; Todorovski I; Fan Z; Abrehart TC; Pomilio G; Wei A; Gregory GP; Vervoort SJ; Brown KK; Johnstone RW
    Cancer Discov; 2021 Jun; 11(6):1582-1599. PubMed ID: 33436370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.